Barbara M. Wollersheim

Mrs. Barbara M. Wollersheim

Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Noord-Holland, The Netherlands
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
LPLonneke V. van de Poll-Franse
Lonneke V. van de Poll-Franse
BRBelle H. de Rooij
Belle H. de Rooij
NHNicole J. E. Horevoorts
Nicole J. E. Horevoorts
AMAnne M. May
Anne M. May
GVGeraldine R. Vink
Geraldine R. Vink
FMFloortje Mols
Floortje Mols
The coronavirus disease 2019 (COVID-19) pandemic has affected cancer care worldwide. In the Netherlands, a lockdown was introduced on March 23, 2020. Planned cancer surgical procedures and systemic treatments were delayed or stopped. The Netherlands Cancer Registry reported a 25% decrease in the absolute number of cancer diagnoses.1 Furthermore, to prevent the potential risk of an infection, patients with cancer were advised to not visit the hospital unless strictly needed.2

8 May 2020 in Journal of Cancer Survivorship
Verified
Journal Article
Closed access
PDF file
BWBarbara M. Wollersheim
Barbara M. Wollersheim
MSMarie-Anne van Stam
Marie-Anne van Stam
RBRuud J.L.H. Bosch
Ruud J.L.H. Bosch
FPFloris J. Pos
Floris J. Pos
CTCorinne N. Tillier
Corinne N. Tillier
NAN.K. Aaronson
N.K. Aaronson

26 April 2021 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
BWBarbara M. Wollersheim
Barbara M. Wollersheim
EHEllis Helweg
Ellis Helweg
CTCorinne N. Tillier
Corinne N. Tillier
HMH. A. M. van Muilekom
H. A. M. van Muilekom
WBWillem de Blok
Willem de Blok
ABAnnelies H. Boekhout
Annelies H. Boekhout

11 October 2023 in JMIR Research Protocols
Verified
Journal Article
Open access
IFItske Fraterman
Itske Fraterman
BWBarbara M. Wollersheim
Barbara M. Wollersheim
VTValentina Tibollo
Valentina Tibollo
SGSavannah Lucia Catherina Glaser
Savannah Lucia Catherina Glaser
SMStephanie Medlock
Stephanie Medlock
SWSofie Wilgenhof
Sofie Wilgenhof
Background: Since treatment with immune checkpoint inhibitors (ICIs) is becoming standard therapy for patients with high-risk and advanced melanoma, an increasing number of patients experience treatment-related adverse events such as fatigue. Until now, studies have demonstrated the benefits of using eHealth tools to provide either symptom monitoring or interventions to reduce treatment-related symptoms such as fatigue. However, an eHealth tool that facilitates the combination of both symptom monitoring and symptom management in patients with melanoma treated with ICIs is still needed. Objective: In this pilot study, we will explore the use of the CAPABLE (Cancer Patients Better Life Experience) app in providing symptom monitoring, education, and well-being interventions on health-related quality of life (HRQoL) outcomes such as fatigue and physical functioning, as well as patients’ acceptance and usability of using CAPABLE. Methods: This prospective, exploratory pilot study will examine changes in fatigue over time in 36 patients with stage III or IV melanoma during treatment with ICI using CAPABLE (a smartphone app and multisensory smartwatch). This cohort will be compared to a prospectively collected cohort of patients with melanoma treated with standard ICI therapy. CAPABLE will be used for a minimum of 3 and a maximum of 6 months. The primary endpoint in this study is the change in fatigue between baseline and 3 and 6 months after the start of treatment. Secondary end points include HRQoL outcomes, usability, and feasibility parameters. Results: Study inclusion started in April 2023 and is currently ongoing. Conclusions: This pilot study will explore the effect, usability, and feasibility of CAPABLE in patients with melanoma during treatment with ICI. Adding the CAPABLE system to active treatment is hypothesized to decrease fatigue in patients with high-risk and advanced melanoma during treatment with ICIs compared to a control group receiving standard care. The Medical Ethics Committee NedMec (Amsterdam, The Netherlands) granted ethical approval for this study (reference number 22-981/NL81970.000.22). Trial Registration: ClinicalTrials.gov NCT05827289; https://clinicaltrials.gov/study/NCT05827289 International Registered Report Identifier (IRRID): DERR1-10.2196/49252

28 June 2022 in Cancers
Verified
Journal Article
Open access
PDF file
BWBarbara M. Wollersheim
Barbara M. Wollersheim
KAKristel M. van Asselt
Kristel M. van Asselt
FPFloris J. Pos
Floris J. Pos
EAEmine Akdemir
Emine Akdemir
SCShifra Crouse
Shifra Crouse
ABAnnelies H. Boekhout
Annelies H. Boekhout
Background: A randomized controlled trial (RCT) is currently comparing the effectiveness of specialist- versus primary care-based prostate cancer follow-up. This process evaluation assesses the reach and identified constructs for the implementation of primary care-based follow-up. Methods: A mixed-methods approach is used to assess the reach and the implementation through the Consolidated Framework for Implementation Research. We use quantitative data to evaluate the reach of the RCT and qualitative data (interviews) to indicate the perspectives of patients (n = 15), general practitioners (GPs) (n = 10), and specialists (n = 8). Thematic analysis is used to analyze the interview transcripts. Results: In total, we reached 402 (67%) patients from 12 hospitals and randomized them to specialist- (n = 201) or to primary care-based (n = 201) follow-up. From the interviews, we identify several advantages of primary care- versus specialist-based follow-up: it is closer to home, more accessible, and the relationship is more personal. Nevertheless, participants also identified challenges: guidelines should be implemented, communication and collaboration between primary and secondary care should be improved, quality indicators should be collected, and GPs should be compensated. Conclusion: Within an RCT context, 402 (67%) patients and their GPs were willing to receive/provide primary care-based follow-up. If the RCT shows that primary care is equally as effective as specialist-based follow-up, the challenges identified in this study need to be addressed to enable a smooth transition of prostate cancer follow-up to primary care.

8 July 2020 in BMC Cancer
Verified
Journal Article
Open access
PDF file
BWBarbara M. Wollersheim
Barbara M. Wollersheim
KAKristel M. van Asselt
Kristel M. van Asselt
HPHenk G. van der Poel
Henk G. van der Poel
HWHenk C. P. M. van Weert
Henk C. P. M. van Weert
MHMichael Hauptmann
Michael Hauptmann
ABAnnelies H. Boekhout
Annelies H. Boekhout
Background: In its 2006 report,From cancer patient to cancer survivor: lost in transition, the U.S. Institute of Medicine raised the need for a more coordinated and comprehensive care model for cancer survivors. Given the ever increasing number of cancer survivors, in general, and prostate cancer survivors, in particular, there is a need for a more sustainable model of follow-up care. Currently, patients who have completed primary treatment for localized prostate cancer are often included in a specialist-based follow-up care program. General practitioners already play a key role in providing continuous and comprehensive health care. Studies in breast and colorectal cancer suggest that general practitioners could also consider to provide survivorship care in prostate cancer. However, empirical data are needed to determine whether follow-up care of localized prostate cancer survivors by the general practitioner is a feasible alternative.Methods: This multicenter, randomized, non-inferiority study will compare specialist-based (usual care) versus general practitioner-based (intervention) follow-up care of prostate cancer survivors who have completed primary treatment (prostatectomy or radiotherapy) for localized prostate cancer. Patients are being recruited from hospitals in the Netherlands, and randomly (1:1) allocated to specialist-based (N = 195) or general practitioner-based (N = 195) follow-up care. This trial will evaluate the effectiveness of primary care-based follow-up, in comparison to usual care, in terms of adherence to the prostate cancer surveillance guideline for the timing and frequency of prostate-specific antigen assessments, the time from a biochemical recurrence to retreatment decision-making, the management of treatment-related side effects, health-related quality of life, prostate cancer-related anxiety, continuity of care, and cost-effectiveness. The outcome measures will be assessed at randomization (≤6 months after treatment), and 12, 18, and 24 months after treatment.Discussion: This multicenter, prospective, randomized study will provide empirical evidence regarding the (cost-) effectiveness of specialist-based follow-up care compared to general practitioner-based follow-up care for localized prostate cancer survivors.Trial registration: Netherlands Trial Registry, TrialNL7068(NTR7266). Prospectively registered on 11 June 2018